RadNet, Inc. (NASDAQ:RDNT), a national leader in
providing high-quality, cost-effective, fixed-site outpatient
diagnostic imaging services through a network of 298 owned and/or
operated outpatient imaging centers, today reported financial
results for its third quarter of 2017.
Dr. Howard Berger, President and Chief Executive
Officer of RadNet, commented, “I am pleased with our results this
quarter. We compared favorably in all metrics relative to last
year’s third quarter despite having divested our Rhode Island
assets in the second quarter, having one less workday in this
year’s third quarter and having overcome a difficult hurricane
season. We demonstrated Revenue, Adjusted EBITDA(1) and
earnings growth as well as positive same center revenue and
procedural increases. Our consistently improving financial
metrics have contributed to material deleveraging since year end
2015.”
Dr. Berger continued, “I believe we are making
great strides by executing on a focused multifaceted
strategy. First, we are streamlining our business through
divesting non-core or lower margin operations. For instance,
we exited Breastlink and our other oncology assets in California as
well as our imaging centers in Rhode Island. Second, we are
continuing to invest in expanding our core markets. As an
example, we doubled the size of our Delaware operating region
through acquiring our principal outpatient competitor, Diagnostic
Imaging Associates. Third, we are continuing to pursue our health
system joint venture strategy. We’ve both expanded existing
joint ventures and established new joint ventures, most notably on
the West Coast with Cedars Sinai. And finally, we continue to
grow our information technology platform, or eRAD, through
acquiring more customers and purchasing or developing additional
software capabilities.”
“During the third quarter, on August 22nd, we
completed an amendment to our senior secured first lien credit
agreement and raised an additional $170 million of first lien term
loans, the proceeds of which were used to repay and retire RadNet’s
second lien term loan. By completing this transaction, we
were able to initially reduce our annual cash interest expense by
almost $3 million. Based upon the pricing matrix in the amendment,
if we continue to deleverage our balance sheet in the future, we
could save up to an additional $3 million of cash interest expense
annually. Furthermore, we were able to extend the maturities
on the $168.0 million portion of term debt which was formerly our
second lien loan by over two years. Lastly, we
significantly improved our financial flexibility,” added Dr.
Berger.
Dr. Berger continued, “What I’m most excited
about is that many of the recent trends in healthcare are
supporting and validating our current operating strategy and
positioning. More and more services are leaving hospitals and
being performed at lower cost ambulatory settings. This is
happening across the delivery system, not just in diagnostic
imaging. This will be a continuing trend as health plans and
their patients seek lower cost alternatives to hospitals. As
an example, Anthem (one of America’s largest health insurers)
recently announced that it will no longer reimburse outpatient
imaging performed at hospitals, except under extraordinary
circumstances. We expect others to follow. We’ve also
noted that insurance companies in their efforts to control costs
are purchasing freestanding, ambulatory providers such as surgery
centers, urgent care locations, clinical laboratories, physical
therapy centers, home health businesses, physician practices and
perhaps even retail drug store locations. I’m more convinced
than ever that RadNet is well positioned to be a major force in the
healthcare delivery continuum of the future.”
Third Quarter Financial
Results
For the third quarter of 2017, RadNet reported
Revenue of $227.6 million, Adjusted EBITDA(1) of $36.1 million and
Net Income of $3.2 million, respectively. Revenue increased
$3.0 million (or 1.3%) and Adjusted EBITDA(1) increased $188,000
(or 0.5%). Adjusting for the sale of the Rhode Island
facilities taken place on April 28, 2017, Revenue increased 1.9%
and Adjusted EBITDA(1) increased 1.3% from the third quarter of
2016.
Net Income increased $1.6 million over the third
quarter of 2016. Per share Net Income for the third quarter
was $0.07, compared to per share Net Income in the third quarter of
2016 of $0.04 (based upon a weighted average number of diluted
shares outstanding of 47.6 million and 46.3 million for these
periods in 2017 and 2016, respectively).
The comparison of Net Income is affected by
certain unusual items which occurred in each of the third quarters
of 2017 and 2016.
During the third quarter of 2017, we had pre-tax
losses related to (i) our divested/closed oncology operations of
$2.0 million; (ii) severance from our sale of Breastlink of $1.0
million; and (iii) expenses from our refinancing transaction of
$235,000. Affecting the third quarter of 2016, we wrote-off
$709,000 of deferred financing fees and expensed $606,000 of
one-time rating agency and legal fees related to our refinancing
transaction completed on July 1, 2016. We also had a one-time
$1.2 million adjustment to depreciation expense and $2.0 million of
severance related to our NY acquisitions.
Adjusting for these events on a tax affected
basis in both quarters, Adjusted Earnings Per Share was $0.12 in
the third quarter of 2017 as compared with $0.11 in the third
quarter of 2016.
Also affecting Net Income in the third quarter
of 2017 (excluding the items mentioned immediately above in the
Adjusted Earnings Calculation) were certain non-cash expenses or
non-recurring items including: $1.5 million of non-cash
employee stock compensation expense resulting from the vesting of
certain options and restricted stock; $139,000 of additional
severance paid in connection with headcount reductions related to
cost savings initiatives; $420,000 loss on the sale or disposal of
certain capital equipment; and $877,000 of amortization of deferred
financing costs and loan discounts related to our credit
facilities.
For the third quarter of 2017, as compared with
the prior year’s third quarter (and excluding Rhode Island from
last year’s third quarter), MRI volume increased 5.1%, CT volume
increased 6.3% and PET/CT volume increased 4.5%. Overall
volume, taking into account routine imaging exams, inclusive of
x-ray, ultrasound, mammography and other exams, increased 2.4% over
the prior year’s third quarter. On a same-center basis,
including only those centers which were part of RadNet for both the
third quarters of 2017 and 2016, MRI volume increased 3.3%, CT
volume increased 5.5% and PET/CT volume increased 2.8%.
Overall same-center volume, taking into account routine imaging
exams, inclusive of x-ray, ultrasound, mammography and other exams,
increased 1.5% compared with the prior year’s same quarter.
Nine Month Financial
Results
For the nine months ended September 30, 2017,
RadNet reported Revenue of $686.6 million, Adjusted EBITDA(1) of
$101.8 million and Net Income of $7.3 million. Revenue
increased $27.0 million (or 4.1%), Adjusted EBITDA(1) increased
$3.7 million (or 3.8%) and Net Income increased $3.5 million,
respectively, over the first nine months of 2016. Net Income
Per Share for the nine month period ended September 30, 2017 was
$0.16 per diluted share, compared to Net Income of $0.08 per
diluted share in corresponding nine month period of 2016 (based
upon a weighted average number of fully diluted shares outstanding
of 47.2 million and 46.7 million for these periods in 2017 and
2016, respectively).
Affecting operating results in the nine months
ended September 30, 2017 were certain non-cash expenses or
non-recurring items including: $5.8 million of non-cash
employee stock compensation expense resulting from the vesting of
certain options and restricted stock; $1.6 million of severance
paid in connection with headcount reductions related to cost
savings initiatives; $828,000 loss on the sale of certain capital
equipment; $3.2 million of expenses related to divested or closed
operations including oncology, Breastlink and Rhode Island;
$235,000 of one-time rating agency and legal fees related to our
refinancing transaction completed on August 22, 2017; $3.1 million
gain on the sale of imaging and medical practice assets including
Breastlink and Rhode Island; and $2.5 million of amortization of
deferred financing costs and loan discounts related to our credit
facilities.
2017 Guidance Update
RadNet reaffirms its previously announced 2017
guidance ranges as follows:
|
|
Total Net Revenue |
$895
million - $925 million |
Adjusted EBITDA(1) |
$135
million - $145 million |
Capital Expenditures (a) |
$55
million - $60 million |
Cash Interest Expense |
$35
million - $40 million |
Free Cash Flow Generation (b) |
$40
million - $50 million |
|
|
(a) Net of proceeds from the sale of equipment, imaging centers
and joint venture interests.
Defined by the Company as Adjusted EBITDA(1)
less total capital expenditures and cash paid for interest.
Dr. Berger added, “We are on track to meet our
guidance ranges for the year. All ranges remain unchanged
from what we announced earlier in the year. Due to lower
interest expense from the refinancing transaction, we may be below
our Cash Interest Expense guidance level for the year.”
Conference Call for Today
Dr. Howard Berger, President and Chief Executive
Officer, and Mark Stolper, Executive Vice President and Chief
Financial Officer, will host a conference call to discuss its third
quarter 2017 results on Thursday, November 9th, 2017 at 7:30 a.m.
Pacific Time (10:30 a.m. Eastern Time).
Conference Call Details:
Date: Thursday, November 9,
2017Time: 10:30 a.m. Eastern TimeDial In-Number:
800-289-0548International Dial-In Number: 719-457-2627
It is recommended that participants dial in
approximately 5 to 10 minutes prior to the start of the 10:30 a.m.
call. There will also be simultaneous and archived webcasts
available at http://public.viavid.com/index.php?id=127114 or
http://www.radnet.com under the “Investors” menu section and “News
Releases” sub-menu of the website. An archived replay of the
call will also be available and can be accessed by dialing
844-512-2921 from the U.S., or 412-317-6671 for international
callers, and using the passcode 6529988.
Regulation G: GAAP and Non-GAAP
Financial Information
This release contains certain financial
information not reported in accordance with GAAP. The Company uses
both GAAP and non-GAAP metrics to measure its financial
results. The Company believes that, in addition to GAAP
metrics, these non-GAAP metrics assist the Company in measuring its
cash-based performance. The Company believes this information
is useful to investors and other interested parties because it
removes unusual and nonrecurring charges that occur in the affected
period and provides a basis for measuring the Company's financial
condition against other quarters. Such information should not
be considered as a substitute for any measures calculated in
accordance with GAAP, and may not be comparable to other similarly
titled measures of other companies. Non-GAAP financial
measures should not be considered in isolation from, or as a
substitute for, financial information prepared in accordance with
GAAP. Reconciliation of this information to the most
comparable GAAP measures is included in this release in the tables
which follow.
About RadNet, Inc.
RadNet, Inc. is the leading national provider of
freestanding, fixed-site diagnostic imaging services in the United
States based on the number of locations and annual imaging revenue.
RadNet has a network of 298 owned and/or operated outpatient
imaging centers. RadNet's core markets include California,
Maryland, Delaware, New Jersey and New York. In addition, RadNet
provides radiology information technology solutions, teleradiology
professional services and other related products and services to
customers in the diagnostic imaging industry. Together with
affiliated radiologists, and inclusive of full-time and per diem
employees and technicians, RadNet has a total of approximately
7,300 employees. For more information, visit
http://www.radnet.com.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Specifically, statements concerning
successfully integrating acquired operations, successfully
achieving 2017 financial guidance, achieving cost savings,
successfully developing and integrating new lines of business,
continuing to grow its business by generating patient referrals and
contracts with radiology practices, and receiving third-party
reimbursement for diagnostic imaging services, are forward-looking
statements within the meaning of the Safe Harbor. Forward-looking
statements are based on management's current, preliminary
expectations and are subject to risks and uncertainties, which may
cause the Company's actual results to differ materially from the
statements contained herein. Further information on potential risk
factors that could affect RadNet's business and its financial
results are detailed in its most recent Annual Report on Form 10-K,
as filed with the Securities and Exchange Commission. Undue
reliance should not be placed on forward-looking statements,
especially guidance on future financial performance, which speaks
only as of the date they are made. RadNet undertakes no obligation
to update publicly any forward-looking statements to reflect new
information, events or circumstances after the date they were made,
or to reflect the occurrence of unanticipated events.
CONTACTS:
RadNet, Inc.Mark
Stolper, 310-445-2800Executive Vice President and
Chief Financial Officer
|
|
RADNET, INC. AND SUBSIDIARIES |
|
CONDENSED CONSOLIDATED BALANCE
SHEETS |
|
(IN THOUSANDS EXCEPT SHARE AND PER SHARE
DATA) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
December 31, |
|
|
|
|
|
|
|
|
|
|
2017 |
|
|
|
2016 |
|
|
|
|
|
|
|
|
|
|
(unaudited) |
|
|
|
ASSETS |
|
CURRENT ASSETS |
|
|
|
|
|
|
|
|
|
Cash and
cash equivalents |
|
|
|
$ |
8,468 |
|
|
$ |
20,638 |
|
|
|
Accounts
receivable, net |
|
|
|
|
168,593 |
|
|
|
164,210 |
|
|
|
Due from
affiliates |
|
|
|
|
|
1,314 |
|
|
|
2,428 |
|
|
|
Prepaid
expenses and other current assets |
|
|
23,181 |
|
|
|
28,435 |
|
|
|
Assets held
for sale |
|
|
|
|
|
- |
|
|
|
2,203 |
|
|
|
|
Total current assets |
|
|
|
|
201,556 |
|
|
|
217,914 |
|
|
PROPERTY AND EQUIPMENT, NET |
|
|
|
245,919 |
|
|
|
247,725 |
|
|
OTHER ASSETS |
|
|
|
|
|
|
|
|
|
Goodwill |
|
|
|
|
|
|
253,140 |
|
|
|
239,553 |
|
|
|
Other
intangible assets |
|
|
|
|
|
40,920 |
|
|
|
42,682 |
|
|
|
Deferred
financing costs |
|
|
|
|
2,035 |
|
|
|
2,004 |
|
|
|
Investment
in joint ventures |
|
|
|
|
49,158 |
|
|
|
43,509 |
|
|
|
Deferred
tax assets, net of current portion |
|
|
48,325 |
|
|
|
50,356 |
|
|
|
Deposits
and other |
|
|
|
|
|
6,866 |
|
|
|
5,733 |
|
|
|
|
Total assets |
|
|
|
|
|
$ |
847,919 |
|
|
$ |
849,476 |
|
|
LIABILITIES AND EQUITY |
|
CURRENT LIABILITIES |
|
|
|
|
|
|
|
|
|
Accounts
payable, accrued expenses and other |
|
$ |
105,100 |
|
|
$ |
111,166 |
|
|
|
Due to
affiliates |
|
|
|
|
|
12,109 |
|
|
|
13,141 |
|
|
|
Deferred
revenue |
|
|
|
|
|
1,944 |
|
|
|
1,516 |
|
|
|
Current
portion of deferred rent |
|
|
|
2,742 |
|
|
|
2,961 |
|
|
|
Current
portion of notes payable |
|
|
|
30,235 |
|
|
|
22,031 |
|
|
|
Current
portion of obligations under capital leases |
|
|
4,617 |
|
|
|
4,526 |
|
|
|
|
Total current liabilities |
|
|
|
|
156,747 |
|
|
|
155,341 |
|
|
LONG-TERM LIABILITIES |
|
|
|
|
|
|
|
|
|
Deferred
rent, net of current portion |
|
|
|
26,225 |
|
|
|
24,799 |
|
|
|
Notes
payable, net of current portion |
|
|
579,921 |
|
|
|
609,445 |
|
|
|
Obligations
under capital lease, net of current portion |
|
|
3,173 |
|
|
|
2,730 |
|
|
|
Other
non-current liabilities |
|
|
|
|
7,895 |
|
|
|
5,108 |
|
|
|
|
Total liabilities |
|
|
|
|
|
773,961 |
|
|
|
797,423 |
|
|
EQUITY |
|
|
|
|
|
|
|
|
|
|
RadNet,
Inc. stockholders' equity: |
|
|
|
|
|
|
|
Common
stock - $.0001 par value, 200,000,000 shares authorized; |
|
|
|
|
|
|
47,536,958, and
46,574,904 shares issued and outstanding at |
|
|
|
|
|
|
|
|
|
|
|
September
30, 2017 and December 31, 2016, respectively |
|
4 |
|
|
|
4 |
|
|
|
Additional
paid-in-capital |
|
|
|
|
210,123 |
|
|
|
198,387 |
|
|
|
Accumulated
other comprehensive (loss) gain |
|
|
(1,376 |
) |
|
|
306 |
|
|
|
Accumulated
deficit |
|
|
|
|
|
(142,885 |
) |
|
|
(150,211 |
) |
|
|
|
Total
RadNet, Inc.'s stockholders' equity |
|
|
65,866 |
|
|
|
48,486 |
|
|
|
Noncontrolling interests |
|
|
|
|
8,092 |
|
|
|
3,567 |
|
|
|
|
Total equity |
|
|
|
|
|
|
73,958 |
|
|
|
52,053 |
|
|
|
|
Total liabilities and equity |
|
|
|
$ |
847,919 |
|
|
$ |
849,476 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RADNET, INC. AND SUBSIDIARIES |
|
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
|
(IN THOUSANDS EXCEPT SHARE DATA) |
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
|
|
|
|
|
|
|
September 30, |
|
September 30, |
|
|
|
|
|
|
|
|
|
|
2017 |
|
|
|
2016 |
|
|
|
2017 |
|
|
|
2016 |
|
|
NET
REVENUE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Service fee
revenue, net of contractual allowances and discounts |
$ |
211,313 |
|
|
$ |
208,430 |
|
|
$ |
638,119 |
|
|
$ |
613,031 |
|
|
|
|
Provision
for bad debts |
|
|
|
|
(11,687 |
) |
|
|
(11,253 |
) |
|
|
(35,187 |
) |
|
|
(33,883 |
) |
|
|
|
Net service
fee revenue |
|
|
|
|
199,626 |
|
|
|
197,177 |
|
|
|
602,932 |
|
|
|
579,148 |
|
|
|
|
Revenue
under capitation arrangements |
|
|
|
27,981 |
|
|
|
27,466 |
|
|
|
83,702 |
|
|
|
80,448 |
|
|
|
|
|
Total net
revenue |
|
|
|
|
227,607 |
|
|
|
224,643 |
|
|
|
686,634 |
|
|
|
659,596 |
|
|
OPERATING EXPENSES |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of
operations, excluding depreciation and amortization |
|
198,109 |
|
|
|
192,752 |
|
|
|
602,174 |
|
|
|
583,640 |
|
|
|
|
Depreciation and amortization |
|
|
|
|
17,053 |
|
|
|
17,318 |
|
|
|
50,319 |
|
|
|
49,541 |
|
|
|
|
Loss (gain)
on sale and disposal of equipment |
|
|
|
420 |
|
|
|
(66 |
) |
|
|
828 |
|
|
|
375 |
|
|
|
|
Severance
costs |
|
|
|
|
|
1,186 |
|
|
|
2,188 |
|
|
|
1,566 |
|
|
|
2,528 |
|
|
|
|
|
Total
operating expenses |
|
|
|
|
216,768 |
|
|
|
212,192 |
|
|
|
654,887 |
|
|
|
636,084 |
|
|
INCOME FROM OPERATIONS |
|
|
|
10,839 |
|
|
|
12,451 |
|
|
|
31,747 |
|
|
|
23,512 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTHER INCOME AND EXPENSES |
|
|
|
|
|
|
|
|
|
|
|
|
Interest
expense |
|
|
|
|
|
10,169 |
|
|
|
11,404 |
|
|
|
30,712 |
|
|
|
32,830 |
|
|
|
|
Meaningful
use incentive |
|
|
|
|
- |
|
|
|
- |
|
|
|
(250 |
) |
|
|
(2,808 |
) |
|
|
|
Equity in
earnings of joint ventures |
|
|
|
(3,450 |
) |
|
|
(2,576 |
) |
|
|
(8,372 |
) |
|
|
(8,129 |
) |
|
|
|
Gain on
sale of imaging centers |
|
|
|
|
(845 |
) |
|
|
- |
|
|
|
(3,146 |
) |
|
|
- |
|
|
|
|
Gain from
return of common stock |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(5,032 |
) |
|
|
|
Other
expenses |
|
|
|
|
|
4 |
|
|
|
174 |
|
|
|
14 |
|
|
|
180 |
|
|
|
|
|
Total other
expenses |
|
|
|
|
5,878 |
|
|
|
9,002 |
|
|
|
18,958 |
|
|
|
17,041 |
|
|
INCOME BEFORE INCOME TAXES |
|
|
|
4,961 |
|
|
|
3,449 |
|
|
|
12,789 |
|
|
|
6,471 |
|
|
|
|
Provision for income taxes |
|
|
|
|
(1,112 |
) |
|
|
(1,461 |
) |
|
|
(4,177 |
) |
|
|
(2,211 |
) |
|
NET
INCOME |
|
|
|
|
|
3,849 |
|
|
|
1,988 |
|
|
|
8,612 |
|
|
|
4,260 |
|
|
|
|
Net income
attributable to noncontrolling interests |
|
|
623 |
|
|
|
344 |
|
|
|
1,286 |
|
|
|
391 |
|
|
NET
INCOME ATTRIBUTABLE TO RADNET,
INC. |
|
|
|
|
|
|
|
|
|
|
|
COMMON STOCKHOLDERS |
|
|
$ |
3,226 |
|
|
$ |
1,644 |
|
|
$ |
7,326 |
|
|
$ |
3,869 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BASIC NET INCOME
PER SHARE |
|
|
|
|
|
|
|
|
|
|
|
|
ATTRIBUTABLE TO RADNET, INC. COMMON
STOCKHOLDERS |
$ |
0.07 |
|
|
$ |
0.04 |
|
|
$ |
0.16 |
|
|
$ |
0.08 |
|
|
DILUTED NET INCOME PER
SHARE |
|
|
|
|
|
|
|
|
|
|
|
|
ATTRIBUTABLE TO RADNET, INC. COMMON
STOCKHOLDERS |
$ |
0.07 |
|
|
$ |
0.04 |
|
|
$ |
0.16 |
|
|
$ |
0.08 |
|
|
WEIGHTED AVERAGE SHARES OUTSTANDING |
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
|
|
|
46,953,705 |
|
|
|
45,868,629 |
|
|
|
46,760,583 |
|
|
|
46,337,993 |
|
|
|
|
Diluted |
|
|
|
|
|
47,577,750 |
|
|
|
46,333,970 |
|
|
|
47,239,360 |
|
|
|
46,748,836 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RADNET, INC. AND SUBSIDIARIES |
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS |
|
(IN THOUSANDS) |
|
(unaudited) |
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, |
|
|
|
|
|
|
|
|
|
|
2017 |
|
|
|
2016 |
|
|
|
CASH FLOWS FROM OPERATING
ACTIVITIES |
|
|
|
|
|
|
|
Net income |
|
|
|
$ |
8,612 |
|
|
$ |
4,260 |
|
|
|
|
Adjustments to reconcile net income |
|
|
|
|
|
|
|
to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
50,319 |
|
|
|
49,541 |
|
|
|
|
Provision for bad debts |
|
|
35,187 |
|
|
|
33,883 |
|
|
|
|
Gain from return of common stock |
|
|
- |
|
|
|
(5,032 |
) |
|
|
|
Equity in earnings of joint ventures |
|
|
(8,372 |
) |
|
|
(8,129 |
) |
|
|
|
Distributions from joint ventures |
|
|
6,785 |
|
|
|
2,929 |
|
|
|
|
Amortization deferred financing costs and loan
discount |
|
|
2,509 |
|
|
|
4,244 |
|
|
|
|
Loss on sale and disposal of equipment |
|
|
828 |
|
|
|
375 |
|
|
|
|
Gain on sale of imaging centers |
|
|
(3,146 |
) |
|
|
- |
|
|
|
|
Stock-based compensation |
|
|
5,842 |
|
|
|
4,918 |
|
|
|
|
Non cash severence |
|
|
1,047 |
|
|
|
- |
|
|
|
|
Changes in operating assets and liabilities, net of
assets |
|
|
|
|
|
|
|
acquired and liabilities assumed in purchase
transactions: |
|
|
|
|
|
|
|
|
Accounts
receivable |
|
|
|
|
(38,770 |
) |
|
|
(53,277 |
) |
|
|
|
Other
current assets |
|
|
|
|
2,981 |
|
|
|
10,420 |
|
|
|
|
Other
assets |
|
|
|
|
309 |
|
|
|
751 |
|
|
|
|
Deferred
taxes |
|
|
|
|
2,031 |
|
|
|
1,426 |
|
|
|
|
Deferred
rent |
|
|
|
|
2,137 |
|
|
|
(678 |
) |
|
|
|
Deferred
revenue |
|
|
|
|
428 |
|
|
|
60 |
|
|
|
|
Accounts payable, accrued expenses and other |
|
|
|
|
6,857 |
|
|
|
9,039 |
|
|
|
|
Net
cash provided by operating activities |
|
|
|
|
|
75,584 |
|
|
|
54,730 |
|
|
|
CASH FLOWS FROM INVESTING
ACTIVITIES |
|
|
|
|
|
|
|
Purchase of imaging facilities |
|
|
(22,904 |
) |
|
|
(6,603 |
) |
|
|
|
Investment at cost |
|
|
(500 |
) |
|
|
- |
|
|
|
|
Purchase of property and equipment |
|
|
(52,807 |
) |
|
|
(52,110 |
) |
|
|
|
Proceeds from sale of imaging and medical practice
assets |
|
|
9,000 |
|
|
|
63 |
|
|
|
|
Cash distribution from new JV partner |
|
|
|
|
|
|
|
1,473 |
|
|
|
994 |
|
|
|
|
Equity contributions in existing and purchase of interest in
joint ventures |
|
|
|
|
|
|
|
(80 |
) |
|
|
(1,374 |
) |
|
|
|
Net
cash used in investing activities |
|
|
|
|
|
(65,818 |
) |
|
|
(59,030 |
) |
|
|
CASH FLOWS FROM FINANCING
ACTIVITIES |
|
|
|
|
|
|
|
Principal payments on notes and leases payable |
|
|
(5,297 |
) |
|
|
(9,219 |
) |
|
|
|
Proceeds from borrowings |
|
|
170,000 |
|
|
|
476,503 |
|
|
|
|
Payments on Term Loan Debt |
|
|
|
|
|
|
|
(188,396 |
) |
|
|
(463,022 |
) |
|
|
|
Deferred financing costs and debt discount |
|
|
(5,067 |
) |
|
|
(945 |
) |
|
|
|
Distributions paid to noncontrolling interests |
|
|
(1,065 |
) |
|
|
(492 |
) |
|
|
|
Proceeds from sale of noncontrolling interest, net of
taxes |
|
|
7,726 |
|
|
|
- |
|
|
|
|
Contributions from noncontrolling partners |
|
|
125 |
|
|
|
- |
|
|
|
|
Proceeds from revolving credit facility |
|
|
182,000 |
|
|
|
344,600 |
|
|
|
|
Payments on revolving credit facility |
|
|
(182,000 |
) |
|
|
(343,000 |
) |
|
|
|
Purchase of noncontrolling interests |
|
|
- |
|
|
|
(350 |
) |
|
|
|
Proceeds from issuance of common stock upon exercise of
options |
|
|
- |
|
|
|
150 |
|
|
|
|
Net
cash (used in) provided by financing activities |
|
|
|
|
|
(21,974 |
) |
|
|
4,225 |
|
|
|
EFFECT OF EXCHANGE RATE CHANGES
ON CASH |
|
|
38 |
|
|
|
(13 |
) |
|
|
NET DECREASE IN CASH AND CASH
EQUIVALENTS |
|
|
(12,170 |
) |
|
|
(88 |
) |
|
|
CASH AND CASH EQUIVALENTS,
beginning of period |
|
|
20,638 |
|
|
|
446 |
|
|
|
CASH AND CASH EQUIVALENTS, end
of period |
|
$ |
8,468 |
|
|
$ |
358 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURE OF CASH
FLOW INFORMATION |
|
|
|
|
|
|
|
Cash paid during the period for interest |
|
$ |
29,134 |
|
|
$ |
26,819 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RADNET, INC. |
RECONCILIATION OF GAAP NET INCOME (LOSS)
ATTRIBUTABLE TO RADNET, INC. |
COMMON SHAREHOLDERS TO ADJUSTED
EBITDA(1) |
(IN THOUSANDS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
|
|
|
|
September 30, |
|
|
|
|
|
|
|
|
|
2017 |
|
|
|
2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income
Attributable to RadNet, Inc. Common Shareholders |
|
|
|
|
$ |
3,226 |
|
|
$ |
1,647 |
|
|
Plus Interest
Expense |
|
|
|
|
|
|
|
10,169 |
|
|
|
11,404 |
|
|
Plus Provision for
Income Taxes |
|
|
|
|
|
|
|
1,112 |
|
|
|
1,458 |
|
|
Plus Depreciation and
Amortization |
|
|
|
|
|
|
|
17,053 |
|
|
|
17,318 |
|
|
Plus Loss (Gain) on
Sale of Equipment |
|
|
|
|
|
|
|
420 |
|
|
|
(66 |
) |
|
Plus Severance
Costs |
|
|
|
|
|
|
|
1,186 |
|
|
|
2,188 |
|
|
Plus Other
Expenses |
|
|
|
|
|
|
|
4 |
|
|
|
174 |
|
|
Plus
Non-Cash Employee Stock-Based Compensation |
|
|
|
|
|
|
1,528 |
|
|
|
1,157 |
|
|
Plus Fees
Related to Term Loan Refinancing |
|
|
|
|
|
|
235 |
|
|
|
606 |
|
|
Plus
Expenses of Divested/Closed Operations |
|
|
|
|
|
|
1,986 |
|
|
|
- |
|
|
Less Gain on Sale of
Imaging Centers |
|
|
|
|
|
|
|
(845 |
) |
|
|
- |
|
|
Adjusted EBITDA(1) |
|
|
|
|
|
|
$ |
36,074 |
|
|
$ |
35,886 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended |
|
|
|
|
|
|
|
|
September 30, |
|
|
|
|
|
|
|
|
|
2017 |
|
|
|
2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income
(Loss) Attributable to RadNet, Inc. Common Shareholders |
|
|
|
|
$ |
7,326 |
|
|
$ |
3,549 |
|
|
Plus Interest
Expense |
|
|
|
|
|
|
|
30,712 |
|
|
|
32,830 |
|
|
Plus Provision for
Income Taxes |
|
|
|
|
|
|
|
4,177 |
|
|
|
2,531 |
|
|
Plus Depreciation and
Amortization |
|
|
|
|
|
|
|
50,319 |
|
|
|
49,541 |
|
|
Plus Loss on Sale of
Equipment |
|
|
|
|
|
|
|
828 |
|
|
|
375 |
|
|
Plus Severance
Costs |
|
|
|
|
|
|
|
1,566 |
|
|
|
2,528 |
|
|
Plus Other
Expenses |
|
|
|
|
|
|
|
14 |
|
|
|
180 |
|
|
Plus
Non-Cash Employee Stock-Based Compensation |
|
|
|
|
|
|
5,842 |
|
|
|
4,918 |
|
|
Plus
Acquisition Related Working Capital Adjustment |
|
|
|
|
|
|
- |
|
|
|
6,072 |
|
|
Plus Fees
Related to Term Loan Refinancing |
|
|
|
|
|
|
235 |
|
|
|
606 |
|
|
Plus
Expenses of Divested/Closed Operations |
|
|
|
|
|
|
3,186 |
|
|
|
- |
|
|
Plus Reimbursable Legal
Expenses |
|
|
|
|
|
|
|
723 |
|
|
|
- |
|
|
Less Gain on Sale of
Imaging Centers |
|
|
|
|
|
|
|
(3,146 |
) |
|
|
- |
|
|
Less Gain on Return of
Common Stock |
|
|
|
|
|
|
|
- |
|
|
|
(5,032 |
) |
|
Adjusted EBITDA(1) |
|
|
|
|
|
|
$ |
101,782 |
|
|
$ |
98,098 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PAYOR CLASS BREAKDOWN** |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Third Quarter |
|
|
|
|
|
|
|
|
2017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial
Insurance |
|
58.9 |
% |
|
|
|
|
|
|
Medicare |
|
20.0 |
% |
|
|
|
|
|
|
Capitation |
|
11.7 |
% |
|
|
|
|
|
|
Workers
Compensation/Personal Injury |
|
3.6 |
% |
|
|
|
|
|
|
Medicaid |
|
2.6 |
% |
|
|
|
|
|
|
Other |
|
3.2 |
% |
|
|
|
|
|
|
Total |
|
100.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
**Capitation percentage has been calculated based upon its
proportion of Revenue Under Capitation Arrangements in the
period to |
Service
Fee Revenue, Net of Contractual Allowances and Discounts plus
Revenue Under Capitation Arrangements. |
After
deducting the capitation percentage from 100%, all other payor
class percentages are based upon a proportion to global
payments |
received
from consolidated imaging centers from that periods dates of
services and excludes payments |
from
hospital contracts, Breastlink, imaging center management fees,
eRAD, Imaging on Call and other miscellaneous revenue. |
|
|
|
|
|
|
|
|
|
|
|
|
|
RADNET PAYMENTS BY MODALITY * |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Third Quarter |
|
Full Year |
|
Full Year |
|
Full Year |
|
|
|
|
2017 |
|
2016 |
|
2015 |
|
2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
MRI |
|
35.2 |
% |
|
34.7 |
% |
|
35.3 |
% |
|
36.1 |
% |
|
|
CT |
|
16.0 |
% |
|
15.8 |
% |
|
15.7 |
% |
|
15.3 |
% |
|
|
PET/CT |
|
5.2 |
% |
|
5.0 |
% |
|
5.1 |
% |
|
5.7 |
% |
|
|
X-ray |
|
8.8 |
% |
|
9.3 |
% |
|
9.6 |
% |
|
10.2 |
% |
|
|
Ultrasound |
|
12.0 |
% |
|
12.3 |
% |
|
11.5 |
% |
|
11.1 |
% |
|
|
Mammography |
|
16.2 |
% |
|
16.5 |
% |
|
16.4 |
% |
|
16.5 |
% |
|
|
Nuclear Medicine |
|
1.1 |
% |
|
1.2 |
% |
|
1.3 |
% |
|
1.4 |
% |
|
|
Other |
|
5.3 |
% |
|
5.2 |
% |
|
5.1 |
% |
|
3.7 |
% |
|
|
|
|
100.0 |
% |
|
100.0 |
% |
|
100.0 |
% |
|
100.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note |
|
|
|
|
|
|
|
|
|
|
* Based
upon global payments received from consolidated Imaging Centers
from that year's dates of service. |
|
Excludes
payments from hospital contracts, Breastlink, Imaging on Call,
eRAD, Center Management Fees and other miscellaneous operating
activities. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Footnotes
(1) The Company defines Adjusted EBITDA as
earnings before interest, taxes, depreciation and amortization,
each from continuing operations and adjusted for losses or gains on
the sale of equipment, other income or loss, debt extinguishments
and non-cash equity compensation. Adjusted EBITDA includes
equity earnings in unconsolidated operations and subtracts
allocations of earnings to non-controlling interests in
subsidiaries, and is adjusted for non-cash or extraordinary and
one-time events taken place during the period.
Adjusted EBITDA is reconciled to its nearest
comparable GAAP financial measure. Adjusted EBITDA is a
non-GAAP financial measure used as analytical indicator by RadNet
management and the healthcare industry to assess business
performance, and is a measure of leverage capacity and ability to
service debt. Adjusted EBITDA should not be considered a
measure of financial performance under GAAP, and the items excluded
from Adjusted EBITDA should not be considered in isolation or as
alternatives to net income, cash flows generated by operating,
investing or financing activities or other financial statement data
presented in the consolidated financial statements as an indicator
of financial performance or liquidity. As Adjusted EBITDA is not a
measurement determined in accordance with GAAP and is therefore
susceptible to varying methods of calculation, this metric, as
presented, may not be comparable to other similarly titled measures
of other companies.
(2) As noted above, the Company defines Free
Cash Flow as Adjusted EBITDA less total Capital Expenditures
(whether completed with cash or financed) and Cash Interest
paid. Free Cash Flow is a non-GAAP financial measure.
The Company uses Free Cash Flow because the Company believes it
provides useful information for investors and management because it
measures our capacity to generate cash from our operating
activities. Free Cash Flow does not represent total cash flow since
it does not include the cash flows generated by or used in
financing activities. In addition, our definition of Free Cash Flow
may differ from definitions used by other companies.
Free Cash Flow should not be considered a
measure of financial performance under GAAP, and the items excluded
from Adjusted EBITDA should not be considered in isolation or as
alternatives to net income, cash flows generated by operating,
investing or financing activities or other financial statement data
presented in the consolidated financial statements as an indicator
of financial performance or liquidity. As Adjusted EBITDA is not a
measurement determined in accordance with GAAP and is therefore
susceptible to varying methods of calculation, this metric, as
presented, may not be comparable to other similarly titled measures
of other companies.
RadNet (NASDAQ:RDNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
RadNet (NASDAQ:RDNT)
Historical Stock Chart
From Apr 2023 to Apr 2024